Grading of chemotherapy-induced peripheral neuropathy

Riaz, 1996, Neurotrophic factors in peripheral neuropathies, Pharmacological strategies. Prog Neurobiol, 49, 125, 10.1016/0301-0082(96)00010-X Dyck, 1997, Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort, Neurology, 49, 229, 10.1212/WNL.49.1.229 Postma, 1997, Chemotherapy-induced peripheral neuropathy, 459 Siegal, 1990, Cisplatin-induced peripheral neuropathy, Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer, 66, 1117 Markman, 1996, Chemotherapy-associated neurotoxicity, An important side effect-impacting on quality, rather than quantity, of life. J Cancer Res Clin Oncol, 122, 511 Schiller, 1994, Phase I trial of three-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer, J Clin Oncol, 12, 241, 10.1200/JCO.1994.12.2.241 Chaudry, 1994, Peripheral neuropathy from taxol and cisplatin combination chemotherapy, Clinical and electrophysiological studies. Neurology, 35, 304 Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014 Ajani, 1990, Comprehensive criteria for assessing therapy-induced toxicity, Cancer Invest, 8, 147, 10.3109/07357909009017560 Vantongelen, 1994 Maser, 1989, Measuring diabetic neuropathy, Assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care, 12, 270 Brundage, 1993, Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data, J Natl Cancer Inst, 85, 1138, 10.1093/jnci/85.14.1138 Postma, 1998, Heimans JJ, Muller MJ et al, Pitfalls in grading seventy of chemotherapy-induced peripheral neuropathy. Ann Oncol, 9, 739 Gerritsenvan der Hoop, 1990, Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer, N Engl J Med, 322, 89, 10.1056/NEJM199001113220204 DeAngelis, 1991, Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin’s lymphoma, Cancer, 67, 2241, 10.1002/1097-0142(19910501)67:9<2241::AID-CNCR2820670905>3.0.CO;2-A Cascinu, 1995, Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial, J Clin Oncol, 13, 26, 10.1200/JCO.1995.13.1.26 Bogliun, 1996, Neurotoxicity of cisplatin ± reduced glutathione in the first-line treatment of advanced ovarian cancer, Int J Gynecol Cancer, 6, 415, 10.1046/j.1525-1438.1996.06050415.x Postma, 1995, Paclitaxel-induced neuropathy, Ann Oncol, 6, 489, 10.1093/oxfordjournals.annonc.a059220 Roberts, 1997, A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer, Gynecol Oncol, 67, 172, 10.1006/gyno.1997.4832 Berger, 1997, Neurological monitoring of neurotoxicity induced by paclitaxel-cisplatin chemotherapy, Eur J Cancer, 33, 1393, 10.1016/S0959-8049(97)00103-2 Dyck, 1980, Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry, Ann Neurol, 8, 590, 10.1002/ana.410080608 Dyck, 1986, Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis, Neurology, 36, 1300, 10.1212/WNL.36.10.1300 Dyck, 1993, Quantitative sensory testing, A consensus report from the peripheral neuropathy association. Neurology, 43, 1050 Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Neurology 1992; 42: 1823–39. Dyck, 1998, Limitations of quantitative sensory testing when patients are biased toward a bad outcome, Neurology, 50, 1213, 10.1212/WNL.50.5.1213 Casey, 1973, Vincristine neuropathy, Clinical and electrophysiological observations. Brain, 96, 69 Roelofs, 1984, Peripheral sensory neuropathy and cisplatin chemotherapy, Neurology, 34, 934, 10.1212/WNL.34.7.934 Riggs, 1988, Prospective nerve conduction studies in cisplatin therapy, Ann Neurol, 23, 92, 10.1002/ana.410230116 Elderson, 1989, Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity, J Neurol Sci, 93, 167, 10.1016/0022-510X(89)90187-1 Lipton, 1989, Taxol produces a predominantly sensory neuropathy, Neurology, 39, 368, 10.1212/WNL.39.3.368 LoMonaco, 1992, Cisplatin neuropathy: Clinical course and neurophysiological findings, J Neurol, 239, 199, 10.1007/BF00839140 Krarup-Hansen, 1993, Examination of distal involvement in cisplatin-induced neuropathy in man, Brain, 116, 1017, 10.1093/brain/116.5.1017 Forsyth, 1997, Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing, J Neurooncol, 35, 47, 10.1023/A:1005805907311 Slevin, 1988, Who should measure quality of life, the doctor or the patient?, Br J Cancer, 57, 109, 10.1038/bjc.1988.20 Stephens, 1997, Randomized trials with quality of life endpoints: Are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings?, Qual Life Res, 6, 225, 10.1023/A:1026458604826 Gill, 1994, A critical appraisal of the quality of quality-of-life measurements, JAMA, 272, 619, 10.1001/jama.1994.03520080061045 Quality of life and clinical trials. Lancet 1995; 346: 1–2 (Editorial). O’Boyle, 1997, Quality of life issues in palliative medicine, J Neurol, 244, S18, 10.1007/PL00007720 Devinsky, 1995, Outcome research in neurology: Incorporating health-related quality of life, Ann Neurol, 37, 141, 10.1002/ana.410370202 Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Cella, 1993, The functional assessment of cancer therapy scale: Development and validation of the general measure, J Clin Oncol, 11, 570, 10.1200/JCO.1993.11.3.570 Bergman, 1994, Aaronson NK, Ahmedzai S et al, The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer, 30A, 635 Sprangers, 1996, The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study, J Clin Oncol, 14, 2756, 10.1200/JCO.1996.14.10.2756 Osoba, 1996, The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires, Qual Life Res, 5, 139, 10.1007/BF00435979 Weitzner, 1995, The Functional Assessment of Cancer Therapy (FACT) scale, Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer, 75, 1151 Cull, 1997, Cancer-specific quality of life questionnaires: The state of the art in Europe, Eur J Cancer, 33, S3, 10.1016/S0959-8049(97)00194-9 Postma, 1999, The impact of chemotherapy-induced peripheral neuropathy on quality of life, J Neurol Neurosurg Psychiatry, 67, 838 Sprangers, 1993, Cull A, Bjordal K et al. The European Organization for Research and Treatment of Cancer approach to quality of life assessment: Guidelines for developing questionnaire modules. Qual Life Res, 2, 287 Hensley, 1999, American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants, J Clin Oncol, 17, 3333, 10.1200/JCO.1999.17.10.3333